Sassicaia Capital Advisers LLC Alzamend Neuro, Inc. Transaction History

Sassicaia Capital Advisers LLC

  • $34.5 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$1.9 - $3.08 $178,147 - $288,786
-93,762 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$2.28 - $7.68 $213,777 - $720,092
93,762 New
93,762 $289,000

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $115M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track This Portfolio

Track Sassicaia Capital Advisers LLC Portfolio

Follow Sassicaia Capital Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sassicaia Capital Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sassicaia Capital Advisers LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email